1Jager E,Nagata Y,Gnjatic S, et al.Monitoring CD8 T cell responses to NY-ESO-1 :correlation of humoral and cellular immune responses[J].Proc Nad Acad Sci USA,2000,97(9) :4760-4765.
2Chen YT, Scanlan MJ, Sa.hin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening[J] .Proc Natl Acad Sci USA, 1997,94(5):1914-1918.
3Rimoldi D, Rubio-Godoy V, Dutoit V, et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonpfimary open reading frame-derived CTL epitopes in melanoma [ J ]. J Immunol, 2000, 165(12) :7253-7261.
4Chen YT, Gure AO, Tsang S, et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library[J] .Proc Natl Acad Sci USA, 1998,95(12) :6919-6923.
5Mandic M, Almunia C, Vicel S, et al. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-hdper 1-type tumor-reactive CD^+ 4 T cells[J].Cancer Res,2003,63(19) :6506-6515.
6Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and maligumt human tissues[J]. Int J Cancer,2001,92(6) :856-860.
7Nakada T, Noguchi Y, Satoh S, et al. NY-ESO- 1 mRNA expression and immunogenlcity in advanced prostate cancer[J]. Cancer Immun,2003,3:10,.
8chen CH, Chen GJ, Lee HS, et al. Expressions of cancer-testis antigens in human hepatocellular carcinomas [ J ]. Cancer Lett, 2001,164 ( 2 ) :189-195.
9Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer[J]. Cancer Res,2003,63(18) :6076-6083.
10Dhodapkar MV, Osman K, Teruya-Feldstein J, et a2. Expression of cancer/testis (CT) antigens MAGE-A 1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site,stage and risk status of disease[J]. Cancer Immun,2003,3:9.
